Clinical Trial Update: Pilot Study of an NTproBNP Guided Strategy of Cardioprotection [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating an NTproBNP-guided cardioprotection strategy to reduce chemotherapy-related cardiotoxicity in cancer patients at risk for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiomyopathy
• Heart Failure
• Lymphoma

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Cardiotoxicity, Toxicity Due to Chemotherapy | Phase 1, Phase 2 | Status: COMPLETED